Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
Werte in diesem Artikel
Danaher Corporation’s DHR first-quarter 2025 adjusted earnings of $1.88 per share beat the Zacks Consensus Estimate of $1.62. However, the bottom line decreased 2.1% year over year.Danaher reported net sales of $5.74 billion, which beat the consensus estimate of $5.56 billion. However, the metric decreased 1% year over year, owing to the lackluster performance of the Diagnostics and Life Sciences segments.DHR’s core sales were flat in the quarter. Acquisitions had a positive impact of 0.5% on quarterly sales while foreign-currency translations had an adverse impact of 1.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)DHR’s Segmental DiscussionRevenues from the Life Sciences segment totaled $1.68 billion, down 3.5% year over year. We expected the segment’s revenues to be $1.62 billion. Core sales decreased 4% year over year. Acquisitions had a positive impact of 2% on segmental sales while foreign-currency translations had a negative impact of 1.5%. Operating profit was $201 million, down 14.5% year over year. Revenues from the Diagnostics segment totaled $2.44 billion, down 3.1% year over year. Our estimate for revenues was $2.35 billion. Core sales decreased 1.5% year over year, while foreign currency had an adverse impact of 1% on sales. Acquisitions/divestitures impacted sales by 0.5%. Operating profit was $718 million, down 13.5% on a year-over-year basis.Revenues from the Biotechnology segment totaled $1.61 billion, up 6% year over year. Our estimate was $1.59 billion. Core sales increased 7% year over year while foreign-currency translations had an adverse impact of 1%. Operating profit was $441 million, up 35.7% year over year.Danaher Corporation Price, Consensus and EPS Surprise Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation QuoteDanaher’s Margin ProfileIn the first quarter, Danaher’s cost of sales decreased 3.4% year over year to $2.2 billion. Gross profit of $3.51 billion increased 0.7% year over year. The gross margin was 61.2% compared with 60.2% in the year-ago quarter.Selling, general and administrative expenses of $1.86 billion recorded an increase of 2.8% on a year-over-year basis. Research and development expenses were $379 million, up 3% year over year.Danaher’s operating profit decreased 2.9% year over year to $1.27 billion. Operating margin contracted to 22.2% from 22.6% in the year-ago quarter.DHR’s Balance Sheet and Cash FlowExiting the first quarter, DHR had cash and equivalents of $2 billion compared with $2.1 billion at 2024-end. Long-term debt was $16 billion at the end of the quarter compared with $15.5 billion at the end of December 2024.Danaher generated net cash of $1.3 billion from operating activities in the first three months of 2025 compared with $1.7 billion in the previous year’s comparable period. Capital expenditures totaled $245 million in the same period, down 15.8% year over year. Adjusted free cash flow decreased 27% year over year to $1.06 billion in the first three months of 2025.In the same period, DHR paid out dividends of $194 million, up 9.6% on a year-over-year basis.Danaher’s OutlookFor the second quarter, Danaher expects adjusted core sales from continuing operations to increase in the low single digits on a year-over-year basis.The metric is anticipated to increase approximately 3% on a year-over-year basis in 2025. The company expects adjusted earnings to be $7.60-$7.75 per share.DHR’s Zacks RankThe company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other CompaniesAZZ Inc. AZZ came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.95. This compares with earnings of $0.93 per share a year ago.AZZ reported revenues of $351.88 million, missing the Zacks Consensus Estimate by 3.77%. This compares with year-ago revenues of $366.5 million. Valmont Industries VMI reported revenues of $969.31 million in the first quarter of 2025, declining 0.9% on a year-over-year basis. EPS of $4.32 for the same period compares with $4.32 a year ago.The reported revenues compare with the Zacks Consensus Estimate of $975.6 million. The company delivered an EPS surprise of 1.89%, with the consensus estimate being $4.24.Pentair plc PNR came out with quarterly earnings of $1.11 per share in the first quarter of 2025, beating the Zacks Consensus Estimate of $1.01. This compares with earnings of $0.94 per share a year ago.Pentair posted revenues of $1.01 billion for the quarter, surpassing the Zacks Consensus Estimate by 2.68%. This compares with year-ago revenues of $1.02 billion.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valmont Industries, Inc. (VMI): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report AZZ Inc. (AZZ): Free Stock Analysis Report Pentair plc (PNR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Danaher und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Danaher
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Danaher
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Danaher Corp.
Analysen zu Danaher Corp.
Datum | Rating | Analyst | |
---|---|---|---|
19.07.2019 | Danaher Buy | Needham & Company, LLC | |
30.05.2019 | Danaher Outperform | Wolfe Research | |
17.04.2019 | Danaher Buy | Needham & Company, LLC | |
28.02.2019 | Danaher Buy | Needham & Company, LLC | |
03.01.2019 | Danaher Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
19.07.2019 | Danaher Buy | Needham & Company, LLC | |
30.05.2019 | Danaher Outperform | Wolfe Research | |
17.04.2019 | Danaher Buy | Needham & Company, LLC | |
28.02.2019 | Danaher Buy | Needham & Company, LLC | |
03.01.2019 | Danaher Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
21.04.2017 | Danaher Sector Perform | RBC Capital Markets | |
27.05.2016 | Danaher Sector Perform | RBC Capital Markets | |
22.04.2016 | Danaher Sector Perform | RBC Capital Markets | |
27.01.2016 | Danaher Sector Perform | RBC Capital Markets | |
23.10.2015 | Danaher Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2006 | Danaher underweight | Prudential Financial |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Danaher Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen